Inhibition of glycogenolysis enhances gluconeogenic precursor uptake by the liver of conscious dogs. Am. J. Physiol. 273 (Endocrinol. Metab. 36): E868-E879, 1997.-We investigated the effect of inhibiting glycogenolysis on gluconeogenesis in 18-h-fasted conscious dogs with the use of intragastric administration of BAY R 3401, a glycogen phosphorylase inhibitor. Isotopic ([3-3 H]glucose and [U-14 C]alanine) and arteriovenous difference methods were used to assess glucose metabolism. Each study consisted of a 100-min equilibration, a 40-min control, and two 90-min test periods. Endogenous insulin and glucagon secretions were inhibited with somatostatin (0.8 µg·kg Ϫ1 · min Ϫ1 ), and the two hormones were replaced intraportally (insulin: 0.25 mU · kg Ϫ1 · min Ϫ1 ; glucagon: 0.6 ng·kg Ϫ1 · min Ϫ1 ). Drug (10 mg/kg) or placebo was given after the control period. Insulin and glucagon were kept at basal levels in the first test period, after which glucagon infusion was increased to 2.4 ng · kg Ϫ1 · min Ϫ1 ; BAY R 3401 decreased tracer-determined endogenous glucose production [rate of glucose production (R a ): 14 Ϯ 1 to 7 Ϯ 1 µmol · kg Ϫ1 · min Ϫ1 ] and net hepatic glucose output (11 Ϯ 1 to 3 Ϯ 2 µmol · kg Ϫ1 · min Ϫ1 ) during test 1. It increased the net hepatic uptake of gluconeogenic substrates from 9.0 Ϯ 2.0 to 11.6 Ϯ 0.6 µmol · kg Ϫ1 · min Ϫ1 . Basal glycogenolysis was decreased by drug (9.1 Ϯ 0.7 to 1.5 Ϯ 0.2 µmol glucosyl U · kg Ϫ1 · min Ϫ1 ). Placebo had no effect on R a or the uptake of gluconeogenic precursors by the liver. The rise in glucagon increased R a by 22 Ϯ 3 and by 8 Ϯ 2 µmol · kg Ϫ1 · min Ϫ1 (at 10 min) in placebo and drug, respectively. The rise in glucagon caused little change in the net hepatic uptake (µmol · kg Ϫ1 · min Ϫ1 ) of gluconeogenic substrates in placebo (8.2 Ϯ 0.6 to 9.0 Ϯ 1.0) but increased it markedly (11.6 Ϯ 0.6 to 15.4 Ϯ 1.0) in drug. Glucagon increased glycogenolysis by 22.1 Ϯ 2.5 and by 7.8 Ϯ 1.6 µmol · kg Ϫ1 · min Ϫ1 in placebo and drug, respectively. The amount of glycogen (µmol glucosyl U/kg) synthesized from gluconeogenic carbon was four times higher in drug (48.6 Ϯ 9.7) than in placebo (11.3 Ϯ 1.7). We conclude that BAY R 3401 caused a marked reduction in basal and glucagonstimulated glycogenolysis. As a result of these changes, there was an increase in the net hepatic uptake of gluconeogenic precursors and in glycogen synthesis.
BAY R 3401; glucagon THE LIVER PRODUCES GLUCOSE via glycogen breakdown and/or gluconeogenesis, and the relative contribution of each to total glucose production changes with altered nutritional and metabolic states. Several studies in dogs and humans have shown that increased delivery of gluconeogenic precursors, such as alanine (11, 39) , glycerol (20, 38) , or lactate (6, 8, 21) , to the liver has no acute effect on the amount of glucose produced by that organ. Delivery of lactate (8) , glycerol (38) , or alanine (11) to postabsorptive dogs in the presence of fixed basal levels of insulin and glucagon increased both the hepatic uptake of these precursors and their conversion into glucose but did not change the total rate of glucose production appreciably. These data support the concept that when gluconeogenesis increases in the liver, glycogenolysis decreases. Gluconeogenic precursors can alter hepatic glycogen metabolism not only by exerting regulatory effects on glycogen phosphorylase and synthase but also by serving as substrates for glycogen synthesis (for review, see Ref. 40) . The above data suggest the existence of an autoregulatory mechanism within the liver such that the desired rate of hepatic glucose output can be maintained regardless of the gluconeogenic precursor supply.
Glucagon is a primary determinant of hepatic glucose production (for review, see Refs. 2 and 19) . In postabsorptive dogs, physiological changes in plasma glucagon have been shown to alter hepatic glucose production through changes in both glycogenolysis and gluconeogenesis (2, 3) . The dose-response relationships between glucagon and hepatic glycogenolysis and gluconeogenesis appear to be similar (33) , but the time courses of the responses are different. The gluconeogenic effect of glucagon is initially small, whereas the glycogenolytic effect is marked (2, 3, 35) . Thereafter, the gluconeogenic effect of glucagon on the liver increases progressively while glucagon-induced glycogenolysis decreases (2, 3, 35) . It is possible, therefore, that the increase in glycogenolysis caused by glucagon limits the initial gluconeogenic effects of the peptide and that the decline in glycogenolysis over time allows gluconeogenesis to increase.
BAY R 3401 is a novel compound that reduces blood glucose levels by inhibiting glycogen phosphorylase in the liver after oral administration (unpublished data). The active metabolite of the compound, BAY U 6751, inhibits the a-and b-forms of the enzyme with an in vitro 50% inhibitory concentration of 55 and 19 ng/ml, respectively. The aim of the present study, therefore, was to assess the effects of inhibiting glycogenolysis (with BAY R 3401) on basal and glucagon-stimulated gluconeogenesis in the conscious dog.
MATERIALS AND METHODS
Animals and surgical procedures. Experiments were performed on 10 overnight-fasted mongrel dogs (17.4-29 .0 kg, mean Ϯ SE 22.4 Ϯ 1.1 kg) of either sex that had been fed a standard meat and chow diet (34% protein-46% carbohydrate-14% fat-6% fiber based on dry wt; Kal Kan, Vernon, CA, and Purina Lab Canine Diet no. 5006, Purina Mills, St. Louis, MO) once daily. The dogs were housed in a facility that met American Association for the Accreditation of Laboratory Animal Care guidelines, and the protocols were approved by the Vanderbilt University Medical Center Animal Care Committee. At least 16 days before an experiment, a laparotomy was performed under general endotracheal anesthesia (15 mg/kg body wt pentobarbital sodium presurgery and 1.0% isoflurane as an inhalation anesthetic during surgery), and catheters for blood sampling were placed into a femoral artery, the portal vein, a hepatic vein, a jejunal vein, and splenic vein as previously described (7, 8, 11, 28, 29, 31, 33, 35, 37) . The catheter for drug infusion was placed into the stomach as previously described (29) . On the day of the experiment, the catheters were exteriorized under local anesthesia (2% lidocaine; Abbott, North Chicago, IL), their contents were aspirated, and they were flushed with saline. Angiocaths (20 gauge; Abbott) were inserted into both cephalic veins for infusion of indocyanine green, radioactive tracers, and glucose and into a saphenous vein for the infusion of somatostatin.
On the day before the experiment, the leukocyte count and hematocrit were determined. Dogs were used for an experiment only if they had 1) a leukocyte count Ͻ18,000/mm 3 , 2) a hematocrit Ͼ38%, 3) a good appetite, and 4) normal stools.
Experimental design. Each experiment consisted of a 100min tracer and dye equilibration period (Ϫ140 to Ϫ40 min), a 40-min control period (Ϫ40 to 0 min), and two 90-min experimental periods (0 to 180 min). A priming dose of [3-3 H]glucose (41.7 µCi) was given at Ϫ140 min. Continuous infusions of [3-3 H]glucose (0.34 µCi/min), [U-14 C]alanine (0.67 µCi/min), and indocyanine green (0.1 mg · m Ϫ2 · min Ϫ1 ) were also started at Ϫ140 min and were continued throughout the experiment. At Ϫ140 min a peripheral infusion of somatostatin (0.8 µg · kg Ϫ1 · min Ϫ1 ) was started to inhibit endogenous insulin and glucagon secretion. Intraportal replacement infusions of insulin (0.25 mU · kg Ϫ1 · min Ϫ1 ) and glucagon (0.6 ng·kg Ϫ1 · min Ϫ1 ) were started simultaneously with initiation of the somatostatin infusion. The plasma glucose level was then monitored every 5 min, and the rate of insulin infusion was adjusted until the plasma glucose level was stabilized at a euglycemic value. Once stabilization had been achieved, the insulin infusion rate was left unchanged. The final infusion rates of insulin used in placebo and drug were 0.26 and 0.24 mU·kg Ϫ1 · min Ϫ1 , respectively. Two experimental protocols were used. An intragastric bolus of a 0.5% methylcellulosesaline solution (50 ml) with (10 mg/kg) (drug group) or without (placebo group) BAY R 3401 was given at 0 min. After a 90-min test period, the infusion rate of glucagon was increased fourfold in both groups for another 90 min.
Analytic procedures. Plasma glucose concentrations and plasma glucose radioactivity ( 3 H and 14 C) were determined as previously described (4, 35) . Plasma [ 14 C]alanine and [ 14 C]lactate specific activities were determined with the use of short-column, ion-exchange chromatography as previously described by Chiasson et al. (4) . Blood concentrations of lactate, alanine, glycerol, ketones, glutamine, and glutamate and plasma concentration of nonesterified fatty acids were determined according to the methods reported previously (7, 8, 29, 35) . Individual blood amino acid levels were assessed with the use of the method of Venkatakrishnan et al. (34) with an interassay coefficient of variation (CV) of 4%. Plasma arterial and hepatic vein indocyanine green concentrations were determined spectrophotometrically at 805 nm (23) .
Liver samples were obtained at the end of the experiments by euthanizing the dog with pentobarbital sodium, exposing the liver by laparotomy, and freeze clamping ϳ5-g liver sections from each lobe. The time elapsed from euthanasia to freeze clamping was Ͻ4 min. The entire liver was then removed from the dog and weighed. The frozen liver samples were stored at Ϫ70°C for subsequent analysis. On the day of the assay, samples were powdered and homogenized, and glycogen concentrations were determined as described previously (18) . Net incorporation of 3 H and 14 C into glycogen was determined after liquid scintillation counting of the processed samples.
Immunoreactive plasma insulin, glucagon, and cortisol and plasma epinephrine and norepinephrine were determined as previously described (35) .
Materials. [3-3 H]glucose (NEN, Boston, MA) was used as the glucose tracer (500 µCi/0.005 mg), and [U-14 C]alanine (Amersham, Chicago, IL) was used as the labeled gluconeogenic precursor (171 mCi/mmol). Indocyanine green was purchased from Hynson, Westcott, and Dunning (Baltimore, MD) and was prepared in sterile water. Insulin was obtained from Squibb-Novo (Princeton, NJ), and glucagon was obtained from Eli Lilly (Indianapolis, IN). Cyclic somatostatin was purchased from Bachem (Torrance, CA). The insulin, glucagon, and somatostatin infusates were prepared with normal saline and contained 3% (vol/vol) of the dog's own plasma. Cortisol radioimmunoassay kits were obtained from Micromedic Systems (Horsham, PA).
Calculations. Hepatic blood flow was assessed by measuring hepatic extraction of indocyanine green (23) . Based on data from Greenway and Stark (17) , the proportions of the hepatic blood supply provided by the hepatic artery and portal vein were assumed to be 28 and 72%, respectively. This ratio conforms to data that we obtained with Doppler flow probes during pancreatic clamps (31) . These proportions were assumed to remain constant throughout all experiments, since treatment did not significantly affect hepatic blood flow. Net hepatic substrate balance was calculated using the formula [H Ϫ (0.28A ϩ 0.72P)] ϫ HF, where A, P, and H are the arterial, portal vein, and hepatic vein substrate concentrations, respectively, and HF is the hepatic blood or plasma flow. When blood levels of the substrate were measured, blood flow was used in the calculation, whereas plasma flow was used when plasma levels were measured. Tracer-determined glucose production and glucose utilization were determined by the method of DeBodo et al. (10) and with the use of the two-compartment model of Mari (25) . The data calculated by the two-compartment model were described. The [ 14 C]glucose production rate was determined using the tracer technique as described by Chiasson et al. (4) .
The hepatic gluconeogenic conversion rate of alanine to glucose and the efficiency of the hepatic gluconeogenesis were calculated by dividing the [ 14 C]glucose production rate [disintegrations · min Ϫ1 (dpm) · kg Ϫ1 · min Ϫ1 ] by the specific activity of alanine (dpm/µmol) entering the liver (using weighted arterial and portal specific activities) and by the rate of net hepatic [ 14 C]alanine uptake, respectively. [ 14 C]lactate was considered in the gluconeogenic calculations (both gluconeogenic conversion and efficiency) only when [ 14 C]lactate was consumed by the liver. In the case of conversion, the specific activity of the precursor pool was estimated by taking into account the relative contribution of [ 14 C]lactate uptake and [ 14 C]alanine uptake by the liver. These contributions were used to determine the average specific activity of these precursors entering the liver. The conversion rate and efficiency are actually minimal estimates of gluconeogenesis because of dilution of the gluconeogenic precursor specific activity within the hepatic oxalacetate pool and the fact that they assess gluconeogenesis from only two precursors. To bracket the true gluconeogenic rate, a maximal estimate can be obtained by assuming that all of the gluconeogenic precursors taken up by the liver are completely converted to glucose, whereas a minimal estimate can be determined by multiplying the maximal estimate by the tracer-determined gluconeogenic efficiency. To use this method, we assumed that the net hepatic uptake of pyruvate was 10% of the net hepatic lactate uptake rate (36) . As reported by McGuinness et al. (28) , the kidney is not a net consumer of alanine, although this organ is capable of gluconeogenesis. Although the kidney is a net consumer of lactate, the amount of 14 C radioactivity in lactate relative to that of alanine was small (Ϸ10%). Therefore, [ 14 C]glucose production by the kidney had little, if any, impact on the calculation of gluconeogenic efficiency.
Hepatic glycogen content was determined by multiplying the glycogen concentration (mg/g of liver) by liver weight. The amount of glycogen synthesized from glucose (the direct pathway) was calculated by dividing 3 H radioactivity incorporated into liver glycogen by the average 3 H specific activity in arterial plasma glucose between 0 and 180 min. The amount of [ 14 C]glucose deposited in glycogen from circulating glucose was determined by multiplying the mass (mg) of glycogen deposited in the liver by the average 14 C specific activity of arterial plasma glucose between 0 and 180 min. The amount of [ 14 C]glucose in glycogen arising from gluconeogenesis (indirect pathway) was calculated by subtracting the [ 14 C]glucose deposited from circulating glucose from the total [ 14 C]glucose in the liver. The amount of glycogen deposition from gluconeogenesis was determined by dividing the radioactivity deposited via gluconeogenesis by the average [ 14 C]lactate specific activity in the hepatic vein (presumed to reflect the intrahepatic pyruvate specific activity) between 0 and 180 min.
Evaluation of inhibitory effect of BAY R 3401 on hepatic glycogen phosphorylase activity. To confirm the effect of BAY R 3401 on glycogenolysis, eight male Sprague-Dawley rats (310-320 g) were fasted for 24 h and divided into two groups. Two hours after oral administration of a 0.5% methylcellulosesaline solution (0.5 ml) with (10 mg/kg) (drug group) or without BAY R 3401 (placebo group), rats were anesthetized with pentobarbital sodium (50 mg/kg body wt, ip). Venous blood was drawn from the external jugular vein, and the major liver lobe was frozen in situ with aluminum tongs precooled in liquid nitrogen. Glycogen phosphorylase activity was analyzed according to the method of Golden et al. (14) .
Two hours after oral administration of the drug or the vehicle to rats, the blood glucose level was lower in drug group (70.2 Ϯ 0.9 mg/dl) than in placebo group (80.3 Ϯ 2.0 mg/dl). Phosphorylase a and total phosphorylase activities (nmol · mg protein Ϫ1 · min Ϫ1 ) were decreased by the drug treatment (7.0 Ϯ 1.9 vs. 14.3 Ϯ 3.1 and 17.3 Ϯ 3.9 vs. 31.1 Ϯ 2.9), respectively. These data confirm the ability of BAY R 3401 to suppress glycogen breakdown.
Statistical analysis. Data are expressed as means Ϯ SE. Statistical comparisons were made with the use of two-way analysis of variance with repeated-measures design. Post hoc analysis was performed with the use of the paired t-test or the unpaired t-test (32) .
RESULTS
Hormone levels and hepatic blood flow. Portal and arterial glucagon levels were basal and unchanged in both protocols during the first two periods. They rose approximately threefold, however, when the glucagon infusion rate was increased ( Fig. 1 ). Portal and arterial insulin levels remained basal and unchanged through-out the study with both placebo and drug administration ( Fig. 1 ). Arterial cortisol (2.2 Ϯ 0.2 in placebo and 2.0 Ϯ 0.4 µg/ml in drug), norepinephrine (174 Ϯ 37 in placebo and 122 Ϯ 21 pg/ml in drug), and epinephrine (96 Ϯ 36 in placebo and 90 Ϯ 25 pg/ml in drug) levels did not change with either treatment. Hepatic blood flow was initially higher in drug group (31 Ϯ 2 ml·kg Ϫ1 · min Ϫ1 ) than in the placebo group (21 Ϯ 2 ml·kg Ϫ1 · min Ϫ1 ), but liver blood flow did not change over time or with treatment in either group.
Glucose kinetics. The plasma glucose level fell slightly in the placebo group before the rise in glucagon while net hepatic glucose output (NHGO) remained unchanged ( Fig. 2 ). With drug administration, NHGO decreased markedly (⌬1.5 mg · kg Ϫ1 · min Ϫ1 by 90 min; P Ͻ 0.05), necessitating glucose infusion (Table 1) to maintain euglycemia. In the placebo group the rise in glucagon infusion increased NHGO by 4.0 Ϯ 0.5 mg·kg Ϫ1 · min Ϫ1 in 10 min (P Ͻ 0.05). NHGO then fell but remained elevated relative to the previous period. As a result of the increase in NHGO, the plasma glucose level rose from 90 Ϯ 3 to 171 Ϯ 18 mg/dl by the end of the study (P Ͻ 0.05). The rise in glucagon in the drug treatment group increased NHGO by 2.0 Ϯ 0.6 http://ajpendo.physiology.org/ mg·kg Ϫ1 · min Ϫ1 within 10 min (P Ͻ 0.05). NHGO then quickly returned to the rate evident in the previous period. As shown in Table 1 , glucose had to be infused in the drug-treated group to maintain euglycemia, even during the period of increased glucagon. Rates of tracer-determined endogenous glucose production (R a ), utilization (R d ), and clearance (Cl) remained unchanged in the placebo group (Table 2) until glucagon increased, at which time R a rose markedly (by 3.7 Ϯ 0.4 mg·kg Ϫ1 · min Ϫ1 at 10 min; P Ͻ 0.05), R d increased by 40% (P Ͻ 0.05), and Cl fell slightly (not significant, Х10%). In the drug treatment group R a fell from 2.5 Ϯ 0.2 to 1.3 Ϯ 0.2 mg · kg Ϫ1 · min Ϫ1 (P Ͻ 0.05) in the first test period, whereas R d and Cl did not change. The rise in glucagon increased endogenous R a by 1.4 Ϯ 0.3 mg·kg Ϫ1 · min Ϫ1 at 10 min (P Ͻ 0.05), after which it fell. R d and Cl increased slightly ( Table 2; 10%; P Ͻ 0.05).
Arterial lactate and alanine levels and net hepatic balances. As shown in Fig. 3 , treatment with placebo did not cause a change in either the arterial lactate level or net hepatic lactate balance. In the presence of placebo the rise in glucagon was associated with an increase in net hepatic lactate production (by 6.7 Ϯ 6.5 µmol · kg Ϫ1 · min Ϫ1 by 10 min), although this change, unlike the rise in the blood lactate level (P Ͻ 0.05), did not reach significance. In contrast, drug administration caused net hepatic lactate output to cease (although, once again, the change was not significant) and stimulated net hepatic lactate uptake of 3.5 Ϯ 1.0 µmol · kg Ϫ1 · min Ϫ1 , despite a fall in the arterial lactate level (567 Ϯ 154 to 374 Ϯ 70 µM; P Ͻ 0.05) before glucagon infusion. The rise in glucagon in the treatment group was associated with a further increase in net hepatic lactate uptake to 7.3 Ϯ 0.8 µmol · kg Ϫ1 · min Ϫ1 (P Ͻ 0.05) and a further decrease in the arterial lactate level (to 290 Ϯ 21 µM by 180 min; P Ͻ 0.05). The lactate level was reduced by Ͼ90% in response to the drug treatment, and the liver consumed rather than produced lactate (P Ͻ 0.05).
As shown in Fig. 4 , treatment with placebo did not affect the arterial blood alanine level, net hepatic alanine uptake, or net hepatic alanine fractional extraction. In the presence of placebo the rise in glucagon did not change the arterial alanine level significantly, but it caused small increases in net hepatic alanine uptake (2.6 Ϯ 0.5 to 3.4 Ϯ 0.4 µmol · kg Ϫ1 · min Ϫ1 ; P Ͻ 0.05) and the net hepatic fractional extraction of alanine (0.36 Ϯ 0.04 to 0.50 Ϯ 0.05; P Ͻ 0.05) by 180 min. With drug administration alanine metabolism did not change significantly until the glucagon concentration rose. The rise in glucagon induced a fall in the arterial alanine level (from 256 Ϯ 40 to 168 Ϯ 15 µM; P Ͻ 0.05) and increases in net hepatic alanine uptake (from 3.3 Ϯ 0.6 to 3.8 Ϯ 0.5 µmol · kg Ϫ1 · min Ϫ1 ) and fractional extraction (from 0.39 Ϯ 0.04 to 0.62 Ϯ 0.06; P Ͻ 0.05). The http://ajpendo.physiology.org/ latter was twofold greater than that seen in the absence of drug.
Arterial glycerol levels and net hepatic balance. Arterial blood glycerol levels, net hepatic glycerol uptake, and net hepatic fractional glycerol uptake remained unchanged with placebo treatment and were unaffected by the fourfold rise in glucagon ( Fig. 5 ). Drug administration caused an increase in net fractional extraction of glycerol by the liver from 0.56 Ϯ 0.05 to 0.66 Ϯ 0.05 by 90 min (P Ͻ 0.05), but neither the arterial glycerol level nor net hepatic glycerol uptake changed significantly. In the presence of drug the rise in glucagon resulted in increases in the net hepatic uptake (from 1.4 Ϯ 0.3 to 1.8 Ϯ 0.3 µmol · kg Ϫ1 · min Ϫ1 ) and fractional extraction of glycerol by the liver (from 0.66 Ϯ 0.06 to 0.81 Ϯ 0.03) by 150 min. These changes were significantly greater than those seen in the absence of drug.
Arterial levels and net hepatic balances of the gluconeogenic amino acids. Arterial glutamine, glycine, serine, and threonine levels and their uptakes by the liver remained unchanged with placebo or drug treatment before glucagon infusion ( Table 3 ). The rise in glucagon shifted net glutamine balance from production to uptake and resulted in a decrease in blood glutamine levels in both groups (P Ͻ 0.05). The blood levels of glycine, serine, and threonine fell in response to glucagon in both groups. Their rates of uptake by the liver were not significantly changed but their net hepatic fractional extractions increased significantly (P Ͻ 0.05).
Gluconeogenic parameters. Net hepatic gluconeogenic substrate uptake, obtained by summing the net hepatic uptakes of lactate, glycerol, pyruvate, and all gluconeogenic amino acids, did not change in the placebo group before or during the period of increased glucagon (Fig. 6) . Likewise, the conversion of gluconeogenic precursors to glucose and gluconeogenic efficiency did not increase in the placebo group (Fig. 7) before glucagon infusion, although gluconeogenic conversion did increase in response to the rise in glucagon. In contrast, drug administration increased net hepatic gluconeogenic precursor uptake by 50% (P Ͻ 0.05), and the rise in glucagon caused a further increase up to 15 µmol · kg Ϫ1 · min Ϫ1 . Gluconeogenic conversion and effi- , and 0 min. Rates of glucose production (R a ) and utilization (R d ) and rate of glucose clearance (Cl) are in ml · kg Ϫ1 · min Ϫ1 . Data are rates before and during a 4-fold increase in intraportal glucagon brought about in presence of basal insulin with or without intragastric administration of BAY R 3401 in 18-h-fasted conscious dogs. * Significantly different from corresponding value in placebo group (P Ͻ 0.05). † Significantly different from control period (P Ͻ 0.05). ciency did not change in response to drug administration, and although glucagon may have increased gluconeogenic conversion slightly, the change was not significant. The amounts of 3 H and 14 C incorporated into liver glycogen by the end of study were two and five times higher, respectively, in the presence of drug than placebo. Glycogen content at 180 min was significantly higher with drug (46.7 Ϯ 0.5 mg/g liver) than placebo (30.9 Ϯ 5.0 mg/g liver). Glycogen synthesis via both the direct and indirect pathways was also higher with drug (66.6 Ϯ 5.5 and 48.6 Ϯ 9.7 µmol glucosyl U/kg body wt) than placebo (41.1 Ϯ 5.1 and 11.3 Ϯ 1.7 µmol glucosyl U/kg body wt) (P Ͻ 0.05).
Arterial nonesterified fatty acid and ketone body levels and net hepatic balance. Arterial levels, net hepatic uptake, and hepatic fractional extraction of Fig. 4 . Arterial blood alanine level and changes in net hepatic alanine uptake and in hepatic alanine fractional extraction before and during a 4-fold increase in intraportal glucagon brought about in presence of basal insulin with or without intragastric administration of BAY R 3401 (drug) in 18-h-fasted conscious dogs. Animals received intragastric bolus injection of vehicle in placebo or of BAY R 3401 (10 mg/kg) at 0 min. Net hepatic alanine uptakes before placebo and drug administration were 2.5 Ϯ 0.3 and 2.9 Ϯ 0.2 µmol · kg Ϫ1 · min Ϫ1 , respectively. Hepatic alanine fractional extractions before placebo and drug administration were 0.34 Ϯ 0.04 and 0.31 Ϯ 0.05, respectively. Values for arterial blood alanine levels are means Ϯ SE and for changes in net alanine uptake and alanine fractional extraction are mean differences Ϯ SE from mean value of each parameter in control period. *Significantly different from corresponding value in placebo group (P Ͻ 0.05). ϩ Significantly different from control period (P Ͻ 0.05). nonesterified fatty acids (NEFA) did not change significantly with placebo or drug treatment before the rise in glucagon (Fig. 8) . The glucagon increment did not alter NEFA levels or uptake in the placebo group. In the drug treatment group, the rise in glucagon increased the net hepatic uptake and fractional extraction of NEFA slightly (P Ͻ 0.05). The arterial level and hepatic production of ketone bodies were not affected by placebo or drug treatment (Fig. 9 ). The rise in glucagon increased ketone body production in the presence of drug but not placebo ( Fig. 9 ).
DISCUSSION
The relative contributions of glycogenolysis and gluconeogenesis to basal glucose production in the present study were the same as those noted in previous studies (2, 3, 7, 35) . Gluconeogenic efficiency increased slightly with time in the placebo group ( Fig. 7; Table 4 ), but this observation agrees with our earlier data (7) . Whether it represents a transition of the animal into a more fasted state or the attainment of tracer equilibration in the metabolite pools of the liver remains unclear (7) . The magnitudes of the increased glucose output, lactate production, and gluconeogenic efficiency induced by hyperglucagonemia in the placebo group (Figs. 2, 3, 7) were similar to those observed in previous studies (33, 35) . The early glucagon-stimulated increase in glucose production must have resulted from an increase in glycogenolysis, because the initial increments in the net uptake of gluconeogenic precursors and gluconeogenic efficiency were very small ( Table 4 ). Glycogenolysis was responsible for at least 80% of the overall increase in glucose production (88% at 100 min and 77% at 180 min) ( Table 4) . A time-dependent decrease in the glycogenolytic response to glucagon has been reported previously (3) , and its cause has been discussed (3) . It can thus be concluded that the placebo (intragastric administration of vehicle) produced no metabolic effects of its own.
Drug treatment, on the other hand, decreased basal hepatic glucose production by 70% and limited the glucagon-induced increase in glucose production by Table 3 . Arterial blood levels and net hepatic uptake of glutamine, glycine, serine, and threonine 
Net hepatic fractional extraction, % 76%. Whereas plasma glucose level was maintained at basal levels during the period of increased glucagon in the drug-treated group, the rise in glucagon elevated plasma glucose level in the placebo group (Fig. 2) . Because hyperglycemia has been shown to limit net hepatic glycogenolysis (2), the effect of drug treatment on the glycogenolytic action of glucagon is even more pronounced than is evident from a comparison of the glucose production rates in the two groups. It is also evident that drug treatment increased the net uptake of gluconeogenic precursors by the liver (Fig. 6 ; Table 4 ). As a result, the maximal contribution of gluconeogenesis to glucose production increased to 80% before the rise in glucagon and was 91% by the end of the glucagon infusion period. Tracer-determined whole body glucose production reflects both hepatic and renal glucose production (1, 28) . In the overnight-fasted dog, the kidney has been shown to produce glucose at rates equal to 13% (28) or 24% (1) of tracer-determined whole body glucose production. With the assumption that renal glucose production, which represents gluconeogenesis, did not change during the treatment with the drug, glucose production at the end of the experimental period was probably entirely due to a combination of renal and hepatic gluconeogenesis. Thus the decreased basal and glucagon-induced glucose production ob-served in the presence of BAY R 3401 was probably the result of an almost complete inhibition of glycogenolysis.
As noted above, the decrease in glycogenolysis brought about by drug treatment increased the basal rate of gluconeogenic precursor uptake by the liver. It also resulted in an increase in the ability of glucagon to stimulate net hepatic gluconeogenic precursor uptake (Fig. 6 ). The latter parameter provides a maximal estimate of gluconeogenesis that closely approximates the directly determined gluconeogenic rate (15) . The increase in the net hepatic uptake of gluconeogenic precursors induced by decreasing glycogenolysis was not accompanied by increases in the rates of gluconeogenic conversion or efficiency (Fig. 7) . Because glycogen synthesis operates simultaneously with glycogen breakdown (9, 24) , an inhibition of glycogenolysis can cause an increase in the retention of 14 C from gluconeogenic precursors in glycogen. If this were the case, true gluconeogenic efficiency would be underestimated by an amount equal to the rate of [ 14 C]glucose deposition in glycogen. Glycogen content at the end of the study was significantly higher in the drug treatment group than in the placebo group, and the amount of 14 C retained in glycogen after drug administration was four times that after placebo treatment. With the assump-tion that 14 C incorporation into glycogen occurred constantly during the 180 min after the control period, the rates of 14 C incorporation into glycogen in placebo and drug were equivalent to 3 and 15% of the hepatic [ 14 C]glucose production rate, respectively. Even if one considers the combination of [ 14 C]glucose production plus [ 14 C]glucose deposition in glycogen, the reduction of glycogenolysis did not enhance gluconeogenic efficiency. With the assumption that the 14 C was incorporated into glycogen only during the rise in glucagon, the rates of 14 C incorporation into glycogen in the placebo and in the drug treatment group corresponded to 8 and 28% of the [ 14 C]glucose production rate during this period. If the [ 14 C]glucose production and [ 14 C]glucose deposition in glycogen are again added, gluconeogenic efficiency increased 17% in placebo and 50% in drug http://ajpendo.physiology.org/ during the rise in glucagon. In this case, the effect of glucagon to increase gluconeogenic efficiency would have increased significantly (P Ͻ 0.05) when glycogenolysis was inhibited. Thus we cannot rule out a change in gluconeogenic efficiency in response to the inhibition of glycogenolysis, but even if it occurred it was not very large.
The drug failed to increase the fractional extraction of gluconeogenic precursors (Figs. 3-5 ). The rates of amino acid uptake by the liver depend on their concentration gradient across the membrane as well as on activity or number of the amino acid transporter(s) (12, 27) . Because there is rapid equilibration between the plasma lactate pool and the intracellular lactate and pyruvate pools (39) , the increase in net hepatic lactate uptake ( Fig. 3) probably reflected a decrease in the intracellular pyruvate levels. Decreased concentration of intracellular pyruvate within the liver might accelerate the transamination of alanine and, as the result, therefore, contribute to the driving force for hepatic amino acid uptake (12) . Because fatty acids have been shown in vitro to inhibit glycolysis and increase gluconeogenesis from lactate, (30) and because fatty acid oxidation has been reported to support the gluconeogenic effect of glucagon (19) , increased fatty acid uptake and the oxidation might serve to augment the glucagoninduced uptake of gluconeogenic precursors.
The rise in glucagon shifted net hepatic glutamine balance from slight net production to net uptake (Table  3) , as observed in a previous study (18) . In contrast to alanine uptake, decreasing glycogenolysis did not affect basal hepatic glutamine balance or glucagon-stimulated net hepatic uptake of this amino acid ( Table 3 ). The regulation of hepatic glutamine metabolism may differ from the regulation of alanine metabolism, because the transporter that mediates the uptake of glutamine (system N) is different from that of alanine (system A) (5) . In addition, glucagon stimulates intracel-lular glutamine degradation via the activation of glutaminase.
Glucagon caused increases in net hepatic NEFA uptake and net hepatic ketone production in drugtreated animals, whereas this peptide had no such effect in the control group, in line with previous studies (22, 35) . The glucagon-induced increases in NEFA uptake and ketogenesis in the drug-treated group were not due to an increased NEFA availability, as indicated by unchanged plasma NEFA levels and increased fractional extraction of free fatty acids (FFA) (Fig. 8) . A study by Goresky et al. (16) in the liver of anesthetized dogs (16) in which the rate constants for transport and metabolism of tracer [1-14 C]palmitate were assessed by means of the multiple-indicator dilution technique suggested that net NEFA uptake is not solely determined by the FFA load but that intracellular factors are equally important. Wasserman et al. (37) showed in conscious dogs that glucagon exerted a ketogenic effect during prolonged exercise and suggested that the effect was on the ketogenic process within the liver. In vitro studies in perfused liver or hepatocytes have shown that glucagon stimulates triglyceride degradation, fatty acid oxidation, and ketogenesis and that it inhibits fatty acid synthesis (13, 26) . Because lactate has an inhibitory effect on ketogenesis in the liver (13), on the other hand, the dramatically reduced blood lactate levels are associated with a reduction in the direct inhibitory effects of hyperglycemia and lactate on hepatic ketogenesis. Consequently, the effects of glucagon on inhibition of hepatic fatty acid synthesis and stimulation of hepatic ketogenesis are more evident, and the resultant decrease in the intracellular concentration of fatty acids might in turn promote an increase in FFA uptake.
In conclusion, the present results show that BAY R 3401 decreased glycogenolysis in the conscious dog. Furthermore, decreased glycogenolysis per se aug- Data are means Ϯ SE in µmol glucosyl U · kg Ϫ1 · min Ϫ1 . Data for control period are means of values at Ϫ40, Ϫ20, and 0 min. Rates are before and during a 4-fold increase in intraportal glucagon in presence of basal insulin with or without intragastric administration of BAY R 3401 in 18-h-fasted conscious dogs. Max GNG cont (endo R a ), maximal contribution of gluconeogenesis (endogenous R a ). * Significantly different from corresponding value in placebo group (P Ͻ 0.05). † Significantly different from control period (P Ͻ 0.05).
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HEPATIC GLYCOGENOLYSIS AND GLUCONEOGENESIS by 10.220.33.2 on September 21, 2017 http://ajpendo.physiology.org/ Downloaded from mented gluconeogenesis by increasing net hepatic gluconeogenic precursor uptake and by increasing FFA metabolism within the liver. This suggests the existence of a reciprocity between glycogenolysis and gluconeogenesis and fatty acid metabolism in maintaining total glucose output by the liver. The augmentation of the gluconeogenic effect of glucagon seen when glycogenolysis was inhibited suggests that the increase in glycogenolysis, which always follows a rise in glucagon, delays and/or represses the gluconeogenic effect of this peptide within the hepatocytes.
